Patent intelligence · US
US 11000588
Etanercept formulations stabilized with sodium chloride
Etanercept formulations stabilized with sodium chloride
Patent details — US 11000588
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 11, 2021
- Expiration
- May 6, 2041
- Applicant
- Coherus BioSciences, Inc.
- Claims
- 19
- CPC classes
- A61K, A61K38/1793, A61K39/39591
Quick answer
US 11000588 (Etanercept formulations stabilized with sodium chloride) is held by Coherus BioSciences, Inc.. Status: granted. Granted May 11, 2021. Expires May 6, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Coherus BioSciences, Inc.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K38/1793, A61K39/39591
More from Coherus BioSciences, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11667702
Stable aqueous formulations of aflibercept
granted -
US 11583584
Stable protein compositions and methods of their use
granted -
US 11576971
Method of filling a container with no headspace
granted -
US 11426446
Stable aqueous formulations of aflibercept
granted -
US 11400072
Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
granted -
US 11396540
Methods for making recombinant proteins
granted -
US 11253508
PPARy agonist for treatment of progressive supranuclear palsy
granted -
US 11229702
High concentration formulations of adalimumab
granted
Related coverage
Frequently asked questions
What is US patent 11000588?
US 11000588 (Etanercept formulations stabilized with sodium chloride) is held by Coherus BioSciences, Inc.. Status: granted. Granted May 11, 2021. Expires May 6, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11000588?
Coherus BioSciences, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 73 pharmaceutical patents for this assignee.
When does US 11000588 expire?
Our index shows an expiration date of May 6, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.